BR112018010155A8 - segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca - Google Patents

segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca

Info

Publication number
BR112018010155A8
BR112018010155A8 BR112018010155A BR112018010155A BR112018010155A8 BR 112018010155 A8 BR112018010155 A8 BR 112018010155A8 BR 112018010155 A BR112018010155 A BR 112018010155A BR 112018010155 A BR112018010155 A BR 112018010155A BR 112018010155 A8 BR112018010155 A8 BR 112018010155A8
Authority
BR
Brazil
Prior art keywords
receptor
fpr2
lipoxin
alx
treatment
Prior art date
Application number
BR112018010155A
Other languages
English (en)
Other versions
BR112018010155A2 (pt
Inventor
Ostrowski Jacek
R Wurtz Nicholas
Garcia Ricardo
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112018010155A2 publication Critical patent/BR112018010155A2/pt
Publication of BR112018010155A8 publication Critical patent/BR112018010155A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se geralmente a uma abordagem terapêutica com base na estimulação da inflamação pelo receptor de formil-peptídeo 2/receptor de lipoxina a4 (fpr2/alx) para o tratamento de doença cardíaca.
BR112018010155A 2015-11-24 2016-11-21 segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca BR112018010155A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259498P 2015-11-24 2015-11-24
PCT/US2016/063036 WO2017091496A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Publications (2)

Publication Number Publication Date
BR112018010155A2 BR112018010155A2 (pt) 2018-11-21
BR112018010155A8 true BR112018010155A8 (pt) 2019-02-26

Family

ID=57544530

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010155A BR112018010155A8 (pt) 2015-11-24 2016-11-21 segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca

Country Status (13)

Country Link
US (1) US20180325869A1 (pt)
EP (1) EP3380091A1 (pt)
JP (1) JP2018538367A (pt)
KR (1) KR20180081528A (pt)
CN (1) CN108348479A (pt)
AU (1) AU2016359463A1 (pt)
BR (1) BR112018010155A8 (pt)
CA (1) CA3006291A1 (pt)
EA (1) EA201891007A1 (pt)
IL (1) IL259468A (pt)
MX (1) MX2018005756A (pt)
SG (1) SG11201803816RA (pt)
WO (1) WO2017091496A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100390A1 (en) 2015-12-10 2017-06-15 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
JP7098663B2 (ja) * 2017-06-09 2022-07-11 ブリストル－マイヤーズ スクイブ カンパニー ピペリジノンホルミルペプチド２受容体アゴニスト
WO2018227065A1 (en) * 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
JP7094989B2 (ja) * 2017-06-09 2022-07-04 ブリストル－マイヤーズ スクイブ カンパニー シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
EA202092094A1 (ru) 2018-03-05 2020-12-10 Бристол-Маерс Сквибб Компани Фенилпирролидиноновые агонисты формилпептидного рецептора 2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE520689T1 (de) * 2007-12-18 2011-09-15 Actelion Pharmaceuticals Ltd Aminotriazolderivate als alx-agonisten
ES2553635T3 (es) * 2010-11-17 2015-12-10 Actelion Pharmaceuticals Ltd. Derivados de éster spiro[2.4]heptano puenteados
CN104284887B (zh) * 2012-05-16 2016-06-22 埃科特莱茵药品有限公司 作为alx受体激动剂的经1-(对-甲苯基)环丙基取代的桥联螺[2.4]庚烷衍生物
WO2017100390A1 (en) * 2015-12-10 2017-06-15 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
EA202092094A1 (ru) * 2018-03-05 2020-12-10 Бристол-Маерс Сквибб Компани Фенилпирролидиноновые агонисты формилпептидного рецептора 2

Also Published As

Publication number Publication date
IL259468A (en) 2018-07-31
US20180325869A1 (en) 2018-11-15
AU2016359463A1 (en) 2018-07-12
MX2018005756A (es) 2018-08-01
BR112018010155A2 (pt) 2018-11-21
SG11201803816RA (en) 2018-06-28
KR20180081528A (ko) 2018-07-16
EA201891007A1 (ru) 2018-11-30
CN108348479A (zh) 2018-07-31
WO2017091496A1 (en) 2017-06-01
EP3380091A1 (en) 2018-10-03
JP2018538367A (ja) 2018-12-27
CA3006291A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
BR112018010155A8 (pt) segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca
CL2018002991A1 (es) Formulaciones de un inhibidor de lsd1.
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CR20190445A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
PE20181156A1 (es) Genes de ataxia de friedreich modificados y vectores para terapia genica
BR112019012062A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos
UY37594A (es) Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
BR112021024236A2 (pt) Proteínas multiespecíficas
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
CO2020001702A2 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
BR112017005202A2 (pt) anticorpos anti-met e composições
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
MX2016016491A (es) Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]